2023
Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study
Oliva E, Platzbecker U, Della Porta M, Garcia-Manero G, Santini V, Fenaux P, Shortt J, Komrokji R, Pelligra C, Guo S, Lord-Bessen J, Xiao H, Yucel A, Miteva D, Rose S, Kreitz S, Sekeres M, Zeidan A. Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study. Blood 2023, 142: 4596. DOI: 10.1182/blood-2023-174660.Peer-Reviewed Original ResearchLower-risk myelodysplastic syndromesEORTC QLQ-C30Patient-reported outcomesErythropoietin-stimulating agentsEpoetin alfaQLQ-C30FACT-AnSustained improvementTreatment armsESA-naïveTransfusion-DependentTreatment tolerabilityStratified Cox proportional hazards regression modelDay 1Cox proportional hazards regression modelCancer Therapy-Anemia (FACT-An) questionnaireLife Questionnaire Core 30Proportional hazards regression modelsMajority of patientsTreatment side effectsPost-baseline visitTransfusion-dependent patientsErythropoiesis stimulating agentsHazards regression modelsPhase 3
2021
IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment.
Platzbecker U, Komrokji R, Fenaux P, Zeidan A, Sekeres M, Savona M, Madanat Y, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Rizo A, Berry T, Feller F, Santini V. IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment. Journal Of Clinical Oncology 2021, 39: tps7056-tps7056. DOI: 10.1200/jco.2021.39.15_suppl.tps7056.Peer-Reviewed Original ResearchInternational Prognostic Scoring SystemErythropoiesis-stimulating agentsPhase 3 partRisk myelodysplastic syndromesMyelodysplastic syndromeRBC-TIRed blood cell (RBC) transfusion-dependent patientsErythropoiesis-stimulating agent treatmentLower-risk myelodysplastic syndromesPhase 2 partProgression of MDSRBC transfusion independenceTransfusion dependent subjectsPlacebo-controlled trialPhase 2/3 studyPhase 3 studyPrognostic scoring systemCurrent treatment optionsTransfusion-dependent patientsQuality of lifeMedian TI durationRate of CRVariant allele frequencyMechanism of actionAdult pts
2018
The effect of iron chelation therapy on overall survival in sickle cell disease and β‐thalassemia: A systematic review
Ballas SK, Zeidan AM, Duong VH, DeVeaux M, Heeney MM. The effect of iron chelation therapy on overall survival in sickle cell disease and β‐thalassemia: A systematic review. American Journal Of Hematology 2018, 93: 943-952. PMID: 29635754, DOI: 10.1002/ajh.25103.Peer-Reviewed Original ResearchConceptsIron chelation therapySickle cell diseaseEvent-free survivalChelation therapyOverall survivalCell diseaseΒ-thalassemiaSystematic reviewRed blood cell transfusionBlood cell transfusionBetter overall survivalSerum ferritin levelsLife-threatening anemiaTransfusion-dependent patientsStandard of careIron chelation agentsLiver iron contentNew oral drugsCell transfusionFrequent transfusionsOral agentsDiabetes mellitusHeart failureLiver cirrhosisFerritin levels
2016
Intensity of end‐of‐life care for patients with myelodysplastic syndromes: Findings from a large national database
Fletcher SA, Cronin AM, Zeidan AM, Odejide OO, Gore SD, Davidoff AJ, Steensma DP, Abel GA. Intensity of end‐of‐life care for patients with myelodysplastic syndromes: Findings from a large national database. Cancer 2016, 122: 1209-1215. PMID: 26914833, DOI: 10.1002/cncr.29913.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overCause of DeathCritical IllnessDatabases, FactualFemaleHospice CareHumansIntensive Care UnitsLogistic ModelsMaleMultivariate AnalysisMyelodysplastic SyndromesOdds RatioPatient Care TeamQuality of Health CareRetrospective StudiesRisk AssessmentSEER ProgramSex FactorsSurvival AnalysisTerminal CareUnited StatesConceptsMyelodysplastic syndromeDays of lifeHospice enrollmentLife careEnd Results-Medicare databaseIntensive care unit admissionEOL quality measuresIntensity of endIntensity of EOLCare unit admissionTransfusion-dependent patientsLarge national databaseUnit admissionPalliative needsNonwhite patientsRed blood cellsMDS patientsPlatelet transfusionsHospice useEOL careHospice modelMultivariable modelLower oddsPatientsPopulation ages
2015
Quality of End-of-Life Care for the Myelodysplastic Syndromes: Findings from a Large National Database
Fletcher S, Cronin A, Zeidan A, Odejide O, Gore S, Davidoff A, Steensma D, Abel G. Quality of End-of-Life Care for the Myelodysplastic Syndromes: Findings from a Large National Database. Blood 2015, 126: 3287. DOI: 10.1182/blood.v126.23.3287.3287.Peer-Reviewed Original ResearchDays of lifeMyelodysplastic syndromeICU admissionLife careSolid tumorsTransfusion-dependent MDS patientsIntensive care unit useBlood cancersMultivariable logistic regression modelBlood pressure supportQuality of EOLMarital statusTransfusion-dependent patientsSpecific hematologic malignanciesQuality of endLarge national databaseYears of ageOdds of enrollmentLogistic regression modelsBone marrow failurePalliative needsHospice enrollmentSurveillance EpidemiologyTransfusion dependenceMDS patients